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Abstract
Platelet membrane glycoprotein (GP) Ib contains receptors for
von Willebrand factor and thrombin. Its proteolytic fragment,
glycocalicin, circulates in normal plasma. In this study, storage
of platelet concentrates for 5 d resulted in a 221% increase in
plasma glycocalicin (1.3 times the total amount of glycocalicin
present on the surface of all platelets), an 8% overall increase
in platelet surface GPIb, and the appearance of a surface
GPIb-negative subpopulation of platelets. Total platelet GPIb
content of fresh washed platelets, determined by gel electro-
phoresis and immunoassay of Triton X-100 lysates, averaged
159,740 molecules per platelet. There were 36,360 surface
GPIb molecules per platelet, determined by immunoassay of
the supernatant of fresh washed platelets whose surface GPIb
had been completely plasmin-cleaved. In sumnpary, these stud-
ies provide evidence for (a) a redistribution of GPIb molecules
with platelet storage, and (b) a large intraplatelet pool ofGPIb
(approximately threefold larger than the platelet surface pool
of GPIb).
Introduction
The platelet surface membrane contains an estimated 26,000-
34,000 glycoprotein (GP)' lb molecules per platelet (1, 2).
Platelet surface GPIb contains receptors for the plasma pro-
teins, von Willebrand factor (1, 3) and thrombin (4, 5). Bind-
ing of von Willebrand factor to its receptor on platelet surface
GPIb is important in the initiation of the process of platelet
adhesion to damaged blood vessel walls (1). Binding ofthrom-
bin to its receptor(s) on platelet surface GPIb is important in
the initiation of the process of platelet activation (4, 5). Glyco-
calicini, a proteolytic fragment of the a-chain of GPIb, circu-
lates in normal plasma at a concentration of 1-3 ,ug/ml (6).
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1. Abbreviations used in this paper: GP, glycoprotein; RSF, relative
specific fluorescence.
The glycocalicin fragment contains the GPIb receptor site for
von Willebrand factor (7) and thrombin (4, 5).
In addition to the platelet surface and plasma pools of
GPIb, there may be a third. intraplatelet pool of GPIb. Both
Asch et al. (8) and Weficel-Drake et al. (9), using frozen thin-
section imtnunoelectron microscopy, have recently described
an intraplatelet pool ofGPIb, located on the intraluminal face
of vacuolar structures (9). However, this putative intraplatelet
pool of GPIb has not been quantitated or functionally charac-
terized.
Ifti the present study, we demonstrate that platelet storage
results in a redistribution of the platelet surface and plasma
pools of GPIb. This redistribution suggested the presence of a
large intraplatelet pool of GPIb, which we have now quanti-
tated.
Methods
Monoclonal antibodies. We utilized three murine monoclonal anti-
bodies (6D1, WM23, and 3G6) directed against the glycocalicin por-
tion of the a-chain of platelet membrane GPIb. 6D1 and WM23 were
generously provided by Drs. Barry S. Coller (SUNY, Stony Brook,
NY) and Michael C. Berndt (University ofSydney, Australia), respec-
tively. 3G6 was prepared in our laboratory by standard hybridoma
technology (10) after injection of mice with glycocalicin, purified as
previously described (I 1). 6DI is directed at the von Willebrand factor
binding site on the glycocalicin portion of the a-chain of GPIb (3).
WM23 and 3G6 are also directed against the glycocalicin portion of
the a-chain ofGPIb, but not against the von Willebrand factor binding
site (Berndt et al. [12] and B. Adelman, unpublished observations).
WM23 has been characterized as being directed against the macrogly-
copeptide portion of glycocalicin, rather than the terminal protein
portion that contains the von Willebrand factor and 6D1 binding sites
(M. C. Berndt, personal communication). Unlike 6D1, both 3G6 and
WM23 recognize their respective antigens in Western blots. After
complete platelet solubilization with sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis (PAGE) and Western blotting, both
3G6 and WM23 (M. C. Berndt, personal communication) recognize
only a single band (GPIb) in both reduced and nonreduced gels. As a
control antibody in the flow cytometry assay, we utilized OX6 (pro-
vided by Dr. Bruce Woda, University of Massachusetts Medical
School), a mouse monoclonal antibody of the same IgG subtype as
6D1 and WM23, but directed at rat lymphocyte Ia antigen.
Platelet concentrate preparation and storage. Blood from five dif-
ferent normal donors was collected into citrate-phosphate-dextrose
solution and individual platelet concentrates, resuspended in - 50 ml
oftheir own plasma, were prepared in PL-732 bags (Fenwal Laborato-
ries, Morton Grove, IL) by standard methods (13). After being left
stationary at 220C for 1 h, the platelet concentrates were stored in a
linear platelet reciprocator model LPR-l (Melco Engineering Corp.,
Glendale, CA) with gentle horizontal agitation at 70 rpm for 5 d at
220C. Immediately after preparation (day 0) and then daily for 5 d,
samples from the platelet concentrates were aseptically withdrawn
through a sample port into a syringe containing EDTA and aprotinin
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(Sigma Chemical Co., St Louis, MO) (final concentrations: EDTA 10
mM, aprotinin 1,000 KIU/ml). For all samples from all donors, each
assay (flow cytometric analysis ofplatelet surface GPIb, enzyme-linked
immunosorbent assay (ELISA) for plasma glycocalicin, and platelet
count) was performed at the same time using the same reagents. There
was no platelet clumping in the concentrates, as determined both by
direct inspection and phase microscopy performed daily for the 5 d of
storage. All donors were normal adult volunteers who had given writ-
ten informed consent for blood collection.
Platelet counts. Platelet counting was performed in a Sysmex auto-
mated hematology analyzer model CC-800 (Toa Medical Electronics,
Carson, CA).
Flow cytometric analysis ofplatelet surface GPIb. Daily samples
removed from the platelet concentrates were fixed in 1% formaldehyde
for 30 min at 220C. As previously described (14-16), platelets were
washed, incubated with either a saturating concentration of mono-
clonal antibody 6D1 or the irrelevant monoclonal antibody OX6,
washed again, incubated with a saturating concentration of fluorescein
isothiocyanate-labeled goat anti-mouse IgG antibody (Cooper Bio-
medical, Malvern, PA), washed again, and analyzed in a FACS 440
(Becton Dickinson FACS Systems, Mountain View, CA). For each
sample the fluorescence signal from 10,000 individual cells was mea-
sured. Three-dimensional contour maps were ungated. All histograms
were gated by forward light scatter to include 90% of cells (excluding
5% of both the smallest and largest cells), with the approximate
median being determined by 2-,gm diam plastic beads (Polysciences,
Inc., Warrington, PA). Based on their characteristic forward and or-
thogonal light scatter profiles (and as confirmed by appropriate mono-
clonal antibodies), no red cells, lymphocytes, monocytes, or granulo-
cytes were among the cells assessed in any of the gated histograms or
ungated contour maps. Results were expressed in one ofthree ways: (a)
the number of platelets with a completely negative surface GPIb phe-
notype, as determined by the percentage of platelets that, after incuba-
tion with monoclonal antibody 6D1 followed by goat anti-mouse an-
tibody, did not have fluorescence > 95% of platelets incubated with
monoclonal antibody OX6 followed by goat antimouse antibody; (b)
relative specific fluorescence (RSF) (arbitrary linear units), calculated
from the mean channel number ofall platelets, as previously described
(15); (c) RSF of surface GPIb-positive platelets, calculated as pre-
viously described (15) but using the mean channel number of only
those platelets that, after incubation with 6D1 followed by goat anti-
mouse antibody, had fluorescence > 95% of platelets incubated with
OX6 followed by goat anti-mouse antibody.
ELISA for plasma glycocalicin. Daily samples removed from the
platelet concentrates were centrifuged at 2,000 g for 10 min at 22°C
and the upper two-thirds ofthe plasma was removed. In control assays,
the plasma was centrifuged at 22°C for an additional 2 h at 100,000 g.
All plasma samples were stored at -70°C until assayed. After thawing,
the samples were centrifuged again at 8,000 g for 4 min at 22°C. The
final plasma supernatants were assessed for glycocalicin content by
ELISA, as previously described (7, 1 1). Briefly, a monolayer of platelets
was fixed to plastic microwells and the ability of diluted plasma sam-
ples to inhibit the binding of monoclonal antibody 6Dl to platelet
surface GPIb was compared to a standard curve of the inhibition of
monoclonal antibody 6D1 binding by known nanomolar concentra-
tions of purified glycocalicin. Parallel assays were performed in which
6D1 was replaced by either monoclonal antibody WM23 or mono-
clonal antibody 3G6. All assays were performed in triplicate.
Total platelet GPIb content determined by ELISA of 1% Triton
X-100-solubilized platelets. Blood from normal donors was drawn
directly into a syringe containing 1/6 vol of acid-citrate-dextrose (triso-
dium citrate 85 mM, citric acid 71 mM, dextrose 11 I mM, pH 4.5),
resulting in a final pH of 6.5, as previously described ( 17). The blood
was centrifuged at 150 g for 15 min at 22°C and the platelet-rich
plasma separated. The platelets were washed twice in Tyrode's buffer
(138 mM NaCl, 29 mM KCI, 12 mM NaHCO3, 0.4 mM NaHPO4,
0.1% glucose, 0.35% bovine serum albumin), pH 6.5, containing 50
ng/ml PGE1, and resuspended in Tyrode's buffer, pH 7.4, containing
50 ng/ml PGE1. The platelets (final concentration 106/,gl) were lysed
by addition of an equal volume of buffer containing 2% Triton X-100
(Sigma Chemical Co.), 100 mM Tris-HCI, pH 7.4, with 2 mg/ml leu-
peptin (Sigma Chemical Co.), as described by Fox et al. (18). The
samples were then centrifuged at 8,000 g for 4 min, conditions that do
not sediment the majority of actin filament-associated GPIb (Fox
[18] and see below). The resulting supernatants were assessed by
ELISA (as described above) for their ability to inhibit either mono-
clonal antibody 6D1 or monoclonal antibody WM23 binding to plate-
let surface GPIb. Each platelet lysate was assayed at two dilutions, each
in triplicate. Platelet lysates from the patient with Bernard-Soulier
syndrome were adjusted to a protein concentration equivalent to that
of normal platelet lysates, as determined by the bicinchoninic acid
protein assay (Pierce Chemical Co., Rockford, IL) performed as pre-
viously described (19).
Total platelet GPIb content determined by SDS-PAGE. As de-
scribed above, platelets were separated from the blood of normal
donors, washed twice in Tyrode's buffer, pH 6.5, containing 50 ng/ml
PGE1, and resuspended in Tyrode's buffer, pH 7.4. SDS-PAGE (5%
polyacrylamide) of platelet pellets was performed according to the
method of Laemmli (20). For each ofsix normal donors, the following
samples were run on a single gel: four dilutions of their whole platelets
(nonreduced); a standard curve of known amounts of glycocalicin
(nonreduced) (purified from multiple donors as previously described
[7]); a standard curve of known molecular weight standards (Bethesda
Research Laboratories, Rockville, MD). The gels were stained with
periodic acid-Schiffs reagent. Densitometry using a Quick Scan R + D
(Helena Laboratories, Beaumont, TX) was performed in triplicate.
The individual peaks corresponding to the GPIb bands (the most
heavily glycosylated; mol wt 163,400) of the whole platelet samples,
and the glycocalicin bands (mol wt 127,600) ofthe standards, were cut
out and weighed. The value for each peak was averaged from the three
scans. The total platelet protein content was determined to be 2.2
X 10-12+0.1 X 10-12 g/platelet (mean±SEM, n = 10) by the bicin-
choninic acid protein assay (19). The amount of GPIb in the whole
platelet samples was calculated by comparison to the standard curve
and use of the following assumptions: (a) Molecular weight of GPIb
was 163,400 and ofglycocalicin 127,600 (by comparison to the known
molecular weight standards). (b) The total carbohydrate content of
GPIb is in the glycocalicin portion (21, 22). 3) The protein/carbohy-
drate ratio and the degree of glycosylation are the same for platelet
surface GPIb and the putative intraplatelet pool ofGPIb (suggested by
the fact that monoclonal antibodies WM23 and 3G6 recognize only a
single band (GPIb) on both Coomassie- and periodic acid-Schiff-
stained Western blots of solubilized platelets).
Plasmin treatment ofwashed platelets. Fresh platelets were washed
as previously described (11), resuspended at a concentration of 1.0
X 106/1I in Tris-EDTA-buffered saline (10 mM Tris, 0.15 M NaCI, 20
mM EDTA, pH 7.4), and incubated for 1 h at 22°C with or without 1
casseinolytic unit/ml ofplasmin (KABI through Helena Laboratories).
The reaction was stopped by adding aprotinin in excess of the amount
needed to totally inhibit plasmin activity (1 1). The platelet suspensions
were then centrifuged (2,000 g, 10 min, 22°C) and the glycocalicin
content of the supernatants determined by ELISA, as described above.
The platelet pellets were resuspended in Tris-EDTA-buffered saline
and fixed overnight at 4°C in 1% formaldehyde. The fixed platelets
were washed three times in Tris-buffered saline (2,000 g, 10 min,
22°C) and resuspended in a concentration of 25,000/4d. Plasmin-
treated and non-plasmin-treated platelets were then analyzed by flow
cytometry for content of surface GPIb, as described above.
Bernard-Soulier syndrome patient. M.R. is a 26-yr-old woman with
the Bernard-Soulier syndrome, as previously described (15).
Results
Fig. 1 shows the effect of length of storage of platelet concen-
trates on plasma glycocalicin concentration, as measured by
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Figure 1. Effect of length of storage of platelet concentrates on
plasma glycocalicin concentration, as determined by ELISA and
monoclonal antibodies 6D1 ( , *), WM23 (- - -, o), and 3G6 (A).
Mean±SEM for five different donors analyzed simultaneously.
ELISA. Between days 0 and 5 there was a 221% increase in
plasma glycocalicin, as determined by monoclonal antibody
6D1. Comparable results were obtained in parallel assays in
which monoclonal antibodies WM23 or 3G6 were used rather
than 6D1 (Fig. 1). This marked rise in plasma glycocalicin was
not the result ofany ofthe following, for the reasons stated: (a)
Platelet lysis: There was no significant change in platelet count
per microliter between day 0 (1,212,000±205,000
[mean±SEM, n = 5]) and day 5 (1,131,000±184,000). (b) Re-
sidual platelets or shedding of platelet membrane microparti-
cles (23): An additional centrifugation of day 5 plasma at
100,000 g (i.e., at forces in excess ofthose required to sediment
platelets and microparticles [23]) resulted in no significant
change (2.2±7.7% [mean±SEM] decrease) in the glycocalicin
concentration of the supernatant. (c) Proteases derived from
contaminating bacteria in the platelet concentrates (24): Mi-
crobiological cultures of all day 5 platelet concentrates were
sterile. (d) In vitro manipulation of samples after their with-
drawal from the platelet concentrate bags: We deliberately
used conditions similar to those for which Coller et al. (6)
demonstrated no in vitro cleavage of glycocalicin, and on day
0 we detected a plasma glycocalicin level (as determined by
monoclonal antibody 6D1) of 43.6±4.6 nM (2.18±0.23 ,gg of
protein/ml) (mean±SEM, n = 5) (Fig. 1), which is similar to
the plasma glycocalicin level of 1-3 ttg/ml that Coller et al. (6)
detected in normal plasma using the same antibody. (e) Fur-
ther proteolysis of glycocalicin in plasma: We have previously
demonstrated that proteolytic digestion of glycocalicin does
not interfere with the epitope recognized by monoclonal anti-
body 6D1 and does not alter the quantity of glycocalicin de-
tected by the ELISA (1 1).
Three lines of evidence suggested that the ELISA was cor-
rectly quantitating plasma glycocalicin. First, the glycocalicin
concentration of normal donor plasma and purified glycocali-
cin was the same whether the samples were quantitated sepa-
rately or in a mixture. Secondly, as stated above, we obtained
plasma glycocalicin levels on day 0 which were comparable to
those obtained in normal donors by Coller et al. (6). Thirdly,
in separate experiments, treatment of washed platelets (1.0
X 106/s1) with plasmin 1 casseinolytic unit/ml for 1 h at 220C
resulted in complete cleavage of platelet surface GPIb, as
quantitated by antibody 6D11 and flow cytometry (as pre-
viously described [ 14]), and release of 36,360±1,390
(mean±SEM, n = 4) molecules of glycocalicin per platelet, as
quantitated by antibody 6D1 in the ELISA (Table I). This
number is consistent with the number of platelet surface GPIb
molecules determined by other investigators (1, 2).
Assuming then that there were initially 36,360 molecules
of GPIb on the surface of each platelet, the observed increase
in plasma glycocalicin concentration between days 0 and 5
corresponded to 1.3 times the total amount of glycocalicin
present on the surface of all the platelets. Fig. 2 shows the effect
of length of storage on the relative number of surface GPIb
molecules per platelet, as determined by monoclonal antibody
6D1 and flow cytometry. Rather than a loss, after 24 h of
storage we observed a 25% increase in the number of surface
GPIb molecules per platelet (Fig. 2: solid circles, solid line).
Over the ensuing 4 d of storage, the number of surface GPIb
molecules per platelet gradually decreased, but by day 5 of
storage there was still an 8% increase in the number of surface
GPIb molecules per platelet compared with day 0 (Fig. 2: solid
circles, solid line).
The flow cytometric method enabled us to determine that
the storage-related increase in the total number of platelet sur-
face GPIb molecules per platelet (Fig. 2) was not the result ofa
uniform increase in the number of GPIb molecules on all
platelets. As shown in Fig. 3, storage of platelets resulted in the
appearance of two phenotypically distinct subpopulations of
platelets: one surface GPIb-positive, the other surface GPIb-
negative. With increasing length of storage, platelets with the
surface GPIb-negative phenotype comprised an increasing
proportion of the total platelet number, comprising 12% of
all platelets by day 5 (Fig. 4 A). After 24 h, platelets with the
surface GPIb-positive phenotype had a 28% increase in the
number of surface GPIb molecules, as determined by flow
cytometry (Fig. 4 B). Over the ensuing 4 d of storage, platelets
with the surface GPIb-positive phenotype gradually expressed
less surface GPIb molecules, but by day 5 of storage there was
still a 16% increase in the number of surface GPIb molecules
compared with this subpopulation of platelets on day 0 (Fig. 4
B). Using the formula: RSFp,,d = (100 - z)/100 X RSFpos,
where RSFp.d is the predicted RSF for all platelets, z is the
percentage of platelets with a completely negative surface
GPIb phenotype, and RSFpOS is the RSF of the GPIb-positive
platelets, we determined that the increase in the number of
surface GPIb molecules in the GPIb-positive subpopulation of
Table I. Number ofGPIb Molecules per Platelet*
Number of GPIb
molecules per platelet Number
(mean±SEM) ofdonors
Whole platelet
SDS-PAGE method 151,800±3,500 6
ELISA (antibody 6D1)t 182,330±6,970 9
ELISA (antibody WM23)t 145,090±6,050 9
Platelet surface
ELISA (antibody 6D1)§ 36,360± 1,390 4
* Assays described in text.
* Determined from 1% Triton X-l00-solubilized platelets.
Determined from supernatant of platelets treated with plasmin I
casseinolytic unit/mi for 1 h at 220C.
1736 Michelson et al.
140-
* 1201
100-
80-
Z * 60-
0
Add 40-
20-
0
0 2
Time (days)
Figure 2. Effect of length of storage of platelet concentrates on the
relative number of surface GPIb molecules per platelet, as deter-
mined by flow cytometry. At each time point for each of the five dif-
ferent donors, RSF was calculated from the mean channel number of
10,000 individually analyzed platelets incubated with monoclonal
antibody 6D1 followed by fluoresceinated goat anti-mouse antibody,
minus the mean channel number of 10,000 individually analyzed
platelets incubated with an irrelevant monoclonal antibody followed
by fluoresceinated goat anti-mouse antibody. Day 0 was arbitrarily
assigned 100 U of fluorescence. Mean±SEM for five different donors
analyzed simultaneously. The observed data are shown as the solid
circles and solid line. The values predicted from Fig. 4 (see Results)
are shown as the open circles and dashed line.
platelets, together with the complete lack ofsurface GPIb mol-
ecules in the GPIb-negative subpopulation of platelets, fully
accounted for the observed increase in the total number of
surface GPIb molecules per platelet (Fig. 2: observed data are
shown as the closed circles and solid line; predicted values are
shown as the open circles and dashed line). Two additional
pieces of information demonstrated by Fig. 3 are that: (a) the
forward light scatter of the platelets decreased with storage,
suggesting that platelet size decreases with storage, and (b) the
forward light scatter of the surface GPIb-negative subpopula-
tion of platelets was less than that ofthe surface GPIb-positive
Control
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subpopulation of platelets, suggesting that the surface GPIb-
negative platelets were smaller than the surface GPIb-positive
platelets.
The unexpectedly large increase in plasma glycocalicin
concentration during storage of platelet concentrates, in the
face ofthe lack ofan overall decrease in platelet surface GPIb,
suggested the existence ofan additional large intraplatelet pool
ofGPIb. In order to quantitate this putative intraplatelet pool
of GPIb, the total platelet GPIb content was determined by
SDS-PAGE. Solubilized whole platelets were compared to a
standard curve of known amounts of purified glycocalicin
(Fig. 5). The total number of GPIb molecules per platelet de-
tected by SDS-PAGE was 151,800±3,500 (mean±SEM, n = 6)
(Table I). The total number ofGPIb molecules per platelet was
therefore approximately fourfold greater than the number of
GPIb molecules present on the platelet surface (Table I), sug-
gesting the presence ofan intraplatelet pool ofGPIb which was
approximately threefold larger than the platelet surface pool of
GPIb.
In order to further substantiate our finding that the total
platelet GPIb content was so much greater than the platelet
surface pool, we quantitated the total platelet GPIb content by
a different method: ELISA of 1% Triton X-100-solubilized
platelets. The total number of GPIb molecules per platelet
detected by ELISA using 6D1 (the monoclonal antibody di-
rected against the von Willebrand factor binding site on GPIb)
was 182,330±6,970 (n = 9). The total number ofGPIb mole-
cules per platelet detected by ELISA using WM23 (the mono-
clonal antibody directed against the macroglycopeptide
portion of the a-chain of GPIb) was 145,090±6,050 (n = 9)
(Table I).
In the assay for total platelet GPIb content determined by
ELISA of Triton X-100 solubilized platelets, the following
three control experiments were performed: (a) replacement of
platelets with buffer only, then treating with 1% Triton X-100,
resulted in the detection of no GPIb (n = 3), thereby demon-
strating that, at the dilutions used, Triton X-100 did not inter-
fere with the ELISA; (b) treatment of normal donor plasma
with 1% Triton X-100 resulted in a plasma glycocalicin level,
Forward Light Scatter a
Figure 3. Effect of length of storage of platelet concentrates on the
number of platelet surface GPIb molecules per platelet, as demon-
strated by three-dimensional contour maps obtained by flow cytome-
try. The vertical axis is a logarithmic scale of fluorescence that corre-
sponds to number of platelet surface GPIb molecules per platelet.
The horizontal axis is a linear scale of forward light scatter that cor-
responds to platelet size. The contour lines represent numbers of
platelets, with the innermost contours corresponding to the highest
numbers of platelets. Each map was obtained from 10,000 individu-
ally analyzed platelets from the same platelet concentrate. (a) Irrele-
vant monoclonal antibody. (b and c) GPIb-specific monoclonal anti-
body (6D1) with platelets from days 0 and 5, respectively.
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lUUl = 4) decrease in the total platelet GPIb content, determined by
ELISA from the supernatants.
80- In order to provide additional evidence that no intraplate-
let factor other than GPIb was interfering with the ELISA for
60- total platelet GPIb content, we studied a patient (M.R.) with
the Bernard-Soulier syndrome. Four serially diluted samples
of her platelet lysates were assessed in the ELISA using both
40- monoclonal antibody 6D1 and monoclonal antibody WM23.
All assays resulted in undetectable levels of GPIb. Given that
20- GPIb, GPV, and GPIX are the only deficiencies known to bepresent in the platelets of patients with the Bernard-Soulier
0 _ I syndrome (26), our data indicate that other intraplatelet fac-
0 tors do not interfere with the ELISA.
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Figure 4. Effect of length of storage of platelet concentrates on sur-
face GPIb-positive and surface GPIb-negative subpopulations of
platelets, as determined by flow cytometry. Surface GPIb-negative
platelets were defined as those platelets that, after incubation with
6Dl followed by goat anti-mouse antibody, did not have fluores-
cence > 95% of platelets incubated with an irrelevant monoclonal
antibody followed by goat anti-mouse antibody. The remainder of
the platelets were defined as surface GPIb-positive. (A) Surface GPIb-
negative platelets, expressed as a percentage of the total number of
platelets. (B) Relative number of surface GPIb molecules on surface
GPIb-positive platelets, as determined by RSF (calculated as in Fig.
2). Mean±SEM for five different donors analyzed simultaneously.
as determined by 6D1, which was 94.4±10.5% (mean±SEM, n
= 3) of the plasma glycocalicin level of untreated normal
plasma, thereby demonstrating that 1% Triton X-100 treat-
ment of glycocalicin did not reveal additional epitopes recog-
nizable by 6D1; (c) within the range 1-10 nM, addition of
various concentrations of purified glycocalicin to the Triton
X-100 platelet lysates had the predicted additive effect on the
GPIb concentration. All platelet lysate samples were therefore
assayed at a dilution within this range.
Fox (18, 25) found that 60-70% of platelet GPIb is bound
to actin filaments and that, after 1% Triton X-100 platelet
solubilization, high-speed centrifugation is required for their
sedimentation. We therefore studied the effect of centrifuga-
tion conditions on quantitation of GPIb in whole-platelet ly-
sates. With all other assay conditions kept constant, changing
the centrifugation conditions of 1% Triton X-100 platelet ly-
sates from our standard (8,000 g for 4 min) to those ofFox (18)
(100,000 g for 3 h) resulted in a 52.8±4.4% (mean±SEM, n
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Figure 5. Total platelet GPIb content, as determined by SDS-PAGE.
(A) Different amounts of solubilized whole platelets were compared
to a standard curve of known amounts of purified glycocalicin. All
samples were nonreduced. Gel was stained with periodic acid-Schiffs
reagent. Densitometric peaks corresponding to the GPIb band (the
most heavily glycosylated; M, 163,400) of the whole-platelet samples,
and the glycocalicin band (M, 127,600) of the standards, were cut
out and weighed. (B) Standard curve of known amounts of purified
glycocalicin. The line of best fit was calculated by linear regression
analysis.
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Discussion
This study demonstrates that platelet storage results in a redis-
tribution ofGPIb molecules, and provides evidence for a large
intraplatelet pool of GPIb. Assuming a total platelet protein
mass of between 1.7 X 10-12 and 3.85 X 10-12 g per platelet
(27), our data suggest that between 0.6% and 1.5% of the total
platelet protein mass is GPIb, making GPIb one of the most
abundant platelet proteins.
The presently described evidence for a large intraplatelet
pool of GPIb is consistent with the findings of other investiga-
tors. Asch et al. (8) and Wencel-Drake et al. (9) used frozen
thin-section immunoelectron microscopy to demonstrate an
intraplatelet pool of GPIb which is distinct from the platelet
surface pool of GPIb. Solum et al. (28) solubilized platelets by
freeze-thawing and, using immunoelectrophoresis, found
67±22 ug of glycocalicin/109 platelets. This corresponds to
287,143±94,286 total GPIb molecules per platelet, a number
comparable to those obtained in our experiments.
This study does not provide information about the location
of the intraplatelet stores of GPIb. However, our previous
work (16) suggests that intraplatelet GPIb is not contained in
a-granules. Whereas thrombin activation is associated with an
increased platelet surface expression of platelet activation-de-
pendent granule-external membrane (PADGEM) protein (a
component of the a-granule membrane of resting platelets)
and release from platelets of f-thromboglobulin and platelet
factor 4 (constituents of a-granules), it is associated neither
with an increased platelet surface expression of GPIb nor with
release of GPIb from platelets (16).
In the ELISA measurement of total platelet GPIb content,
our calculations assume that one molecule of GPIb and one
molecule of glycocalicin each bind only one molecule of 6D1
antibody. With regard to the possibility that a repeating epi-
tope for antibody 6D1 is revealed by solubilization and per-
haps unfolding of the extensive carbohydrate portion ofGPIb,
we make the following points: 1. The epitope for monoclonal
antibody 6D1 is not in the carbohydrate portion of GPIb,
because 6D1 binding to glycocalicin is not altered by (a) the
removal from glycocalicin of all its sialic acid and galactose
residues and part of its N-acetyl glucosamine residues (7), or
(b) the complete deglycosylation ofglycocalicin (R. I. Handin,
unpublished observations). 2. We have previously demon-
strated that proteolytic digestion of glycocalicin does not re-
veal additional epitopes recognized by 6D1 (11). 3. In the
present experiments we determined that 1% Triton X-100
treatment of glycocalicin did not reveal additional epitopes
recognizable by 6D1 or WM23. 4. Comparable results for the
total platelet GPIb content were obtained with antibodies 6D1
and WM23, despite each antibody being directed against a
different part of the GPIb molecule.
Fox (18, 25) reported that 60-70% of platelet GPIb is
bound to actin filaments present in the platelet skeleton. Fox
(18) demonstrated that, after 1% Triton X-100 solubilization
of platelets in the presence of 1 mg/ml leupeptin, the actin
filament-associated GPIb is recovered mainly with those fila-
ments which require high-speed centrifugation (100,000 g for
3 h) for their sedimentation, whereas low-speed centrifugation
(15,600 g for 4 min) results in most of the GPIb being in the
supernatant. Likewise, Solum and Olsen (29) demonstrated
that solubilization of platelets with 1% Triton X-100 in the
presence of leupeptin resulted in essentially all the GPIb being
in the supernatant after low-speed centrifugation (8,000 g for 4
min) of the lysate. Consistent with the data of both Fox and
Solum and their co-workers, we found that, after 1% Triton
X-100 solubilization of platelets in the presence of 1 mg/ml
leupeptin, alteration of the centrifugation conditions of the
platelet lysates from our standard (8,000 g for 4 min) to those
of Fox (18) (100,000 g for 3 h) resulted in a 52.8±4.4%
(mean±SEM, n = 4) decrease in the GPIb content of the su-
pernatant, as determined by ELISA. We conclude that our
low-speed centrifugation conditions do not sediment the ma-
jority ofactin filament-associated GPIb and that ELISA ofthis
supernatant assays most of the total platelet GPIb content.
The present studies did not enable us to determine that the
surface GPIb-negative phenotype was the result of a complete
deficiency of platelet surface GPIb. A partial deficiency of the
platelet surface GPIb molecule or a more subtle biochemical
modification ofthe antibody binding site are alternative expla-
nations for the lack ofbinding of monoclonal antibody 6Dl to
the subpopulation of platelets with the surface GPIIb-negative
phenotype. Although thrombin can result in decreased bind-
ing of6D1 to platelets (16), generation ofthrombin would not
account for the marked increase in plasma glycocalicin (16).
The present data are relevant to the clinical infusion of
platelet concentrates into patients, because (a) monoclonal
antibody 6D1 is directed against the GPIb receptor for von
Willebrand factor (3), (b) this receptor has a central role in
platelet adhesion to damaged blood vessel walls (1), and (c) our
experiments were performed on platelet concentrates prepared
exactly as for clinical transfusion purposes (13). Studies by
other investigators of the GPIb content of stored platelet con-
centrates have yielded apparently confficting results. In two
separate radioligand-binding assays utilizing a monoclonal
antibody (AN5 1) directed at GPIb and Maclura pomifera lec-
tin, respectively, Taylor and Anstee (30) found no decrease in
the surface GPIb content ofstored platelet concentrates after 3
d of storage at 22°C. Using SDS-PAGE of whole platelets and
periodic acid Schiffs reagent staining, George (31) and Bolin
et al. (32) found a 49% and a 29% decrease, respectively, in the
total GPIb content of stored platelet concentrates after 3 d of
storage at 22°C. The data of all these investigators (30-32) are,
however, consistent with the present finding ofa redistribution
of GPIb molecules.
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